Elizabeth A. Mittendorf, Guy T. Clifton, Jarrod P. Holmes, Kevin S. Clive, Ritesh Patil, Linda C. Benavides, Jeremy D. Gates, Alan K. Sears, Alexander Stojadinovic, Sathibalan Ponniah and George E. Peoples Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients Cancer 118
Article first published online: 11 OCT 2011 | DOI: 10.1002/cncr.26574
A phase 1-2 clinical trial vaccinating human leukocyte antigen A2/A3+ breast cancer patients with the human epidermal growth receptor 2 (HER2)-derived E75 vaccine in the adjuvant setting has been completed. The vaccine has clinical efficacy that is more prominent in certain patients, including those with lymph node-positive, HER2 immunohistochemistry 1+ or 2+, or grade 1 or 2 disease who received the optimal vaccine dose.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.